Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS IG Calls On Drug Makers To Heed Marketing Laws After Report On Rampant Inappropriate Use Of Atypical Antipsychotics In Medicare

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS Inspector General finds 88% of Medicare claims for atypical antipsychotic drugs for elderly nursing home residents were used in patients with dementia, despite strict warnings in product labeling.

You may also be interested in...



Long-Acting Antipsychotic Sampling Program In Hospitals Cleared By OIG Advisory Opinion

Sample program focuses only on inpatient use and in hospitals that do not accept Prescription Drug Marketing Act-compliant trial units. By improving adherence, program could lower federal health care costs over time, Office of Inspector General suggests.

CMS Initiative To Lower Antipsychotic Drug Use In Nursing Homes Showing Success

A program launched in 2012, the National Partnership to Improve Dementia Care, is on its way to meeting goals of lowering the use of antipsychotic drugs in nursing homes by 15%, with 11 states already hitting that target.

Nursing Home Overprescribing: Pharmacist Independence Requirement Should Start As Demo, APhA Says

CMS’ proposal to reduce overprescribing in nursing homes draws cautiously favorable response from national pharmacist group, but long-term care pharmacy firm Omnicare argues the agency has not provided adequate justification for its plan.

Related Content

Topics

UsernamePublicRestriction

Register

PS072214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel